Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Perspective Therapeutics, Inc.CATX · Entity 694 | VP Finance/Prin Fin&Acct Offic | July 17, 2024 | July 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Perspective Therapeutics, Inc.
Report date July 17, 2024 · Filed July 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.96 · Expires 2034-07-17 | Direct | 34,500 |
Reported balance
After 2024-07-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-17 · Grant · Acquired 34,500 · Balance 34,500 F1: Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the monthly anniversary after the Grant Date (07/17/2024), subject to a continued service relationship. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the monthly anniversary after the Grant Date (07/17/2024), subject to a continued service relationship.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 17, 2024 Filed Jul 19, 2024 11:36 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock Option (right to buy) · Derivative | 34,500 | $0.00 Strike: $11.96 | $0.00 |
DisclosureSEC source: 0000950170-24-084754 · ownership.xml · derivative · entry 1 Austin Mark John · CIK 0001713059 · VP Finance/Prin Fin&Acct Offic 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,500 Underlying: Common Stock · 34,500 shares Expires 2034-07-17 F1 · derivative.exercise_date: Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the monthly anniversary after the Grant Date (07/17/2024), subject to a continued service relationship. Read SEC document |
| April 23, 2024 Filed Apr 24, 2024 20:35 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | Exercise / conversionStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0000950170-24-047645 · ownership.xml · derivative · entry 2 Austin Mark John · CIK 0001713059 · VP Finance/Prin Fin&Acct Offic 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 150,000 shares Expires 2032-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock Option is fully vested. Read SEC document |
| April 23, 2024 Filed Apr 24, 2024 20:35 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | Exercise / conversionCommon stock | 30,000 | $0.36 | $10,800.00 |
DisclosureSEC source: 0000950170-24-047645 · ownership.xml · nonDerivative · entry 1 Austin Mark John · CIK 0001713059 · VP Finance/Prin Fin&Acct Offic 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 20:45 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock Options (right to buy) · Derivative | 225,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001437749-23-017422 · rdgdoc.xml · derivative · entry 1 Austin Mark John · CIK 0001713059 · VP Finance/Prin Fin&Acct Offic 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 773,115 Underlying: Common Stock · 225,000 shares Expires 2033-06-12 F1 · derivative.exercise_date: 25% vested as of 6/12/2023, and the remaining 75% will vest over the next three (3) years, commencing on 6/12/2024, until fully vested. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 23:04 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001437749-22-020203 · rdgdoc.xml · derivative · entry 1 Austin Mark John · CIK 0001713059 · VP Finance/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 548,115 Underlying: Common Stock · 150,000 shares Expires 2032-08-09 F1 · derivative.exercise_date: 25% vested as of 8/9/2022, and the remaining 75% will vest over the next three (3) years, commencing on 8/9/2023, until fully vested. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 00:24 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 13,800 | $0.29 | $3,959.22 |
DisclosureSEC source: 0001437749-22-014723 · rdgdoc.xml · nonDerivative · entry 2 Austin Mark John · CIK 0001713059 · VP Finance/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,030 Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 00:24 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 5,000 | $0.29 | $1,425.00 |
DisclosureSEC source: 0001437749-22-014723 · rdgdoc.xml · nonDerivative · entry 1 Austin Mark John · CIK 0001713059 · VP Finance/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,230 Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:31 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 133,500 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001437749-21-016456 · rdgdoc.xml · derivative · entry 1 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,115 Underlying: Common Stock · 133,500 shares Expires 2031-07-01 F1 · derivative.exercise_date: 25% vested as of 7/1/2021, and the remaining 75% will vest over the next three (3) years, commencing on 7/1/2022, until fully vested. Read SEC document |
| October 22, 2020 Filed Oct 28, 2020 20:46 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseWarrant (right to buy) · Derivative | 9,615 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001437749-20-021861 · rdgdoc.xml · derivative · entry 2 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,615 Underlying: Common Stock · 9,615 shares Expires 2025-10-22 F2 · shares: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. F2 · derivative.exercise_date: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. F2 · derivative.expiration_date: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. Read SEC document |
| October 22, 2020 Filed Oct 28, 2020 20:46 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 19,230 | $0.52 | $9,999.60 |
DisclosureSEC source: 0001437749-20-021861 · rdgdoc.xml · nonDerivative · entry 1 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,230 F1 · shares: Purchased pursuant to public offering that closed on October 22, 2020. F1 · price: Purchased pursuant to public offering that closed on October 22, 2020. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 20:46 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001437749-20-013878 · rdgdoc.xml · derivative · entry 1 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: 25% vested as of 6/23/2020, and the remaining 75% will vest over the next three (3) years, commencing on 6/23/2021, until fully vested. Read SEC document |
| June 18, 2019 Filed Jun 24, 2019 20:56 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001437749-19-012554 · rdgdoc.xml · derivative · entry 1 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: 25% vested as of 6/18/2019, and the remaining 75% will vest over the next three (3) years, commencing on 6/18/2020, until fully vested. Read SEC document |
| November 16, 2018 Filed Nov 21, 2018 00:21 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 4,283 | $0.40 | $1,702.92 |
DisclosureSEC source: 0001437749-18-021156 · rdgdoc.xml · nonDerivative · entry 1 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 23:58 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 2,452 | $0.41 | $1,005.32 |
DisclosureSEC source: 0001437749-18-020969 · rdgdoc.xml · nonDerivative · entry 1 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,717 Read SEC document |
| June 13, 2018 Filed Jun 20, 2018 00:29 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001437749-18-012099 · rdgdoc.xml · derivative · entry 1 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 100,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: 25% vested as of 6/13/2018, and the remaining 75% will vest over the next three (3) years, commencing on 6/13/2019, until fully vested. Read SEC document |
| November 24, 2017 Filed Nov 24, 2017 22:16 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 1,025 | $0.49 | $502.25 |
DisclosureSEC source: 0001437749-17-019783 · rdgdoc.xml · nonDerivative · entry 6 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,265 Read SEC document |
| November 24, 2017 Filed Nov 24, 2017 22:16 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 515 | $0.50 | $254.93 |
DisclosureSEC source: 0001437749-17-019783 · rdgdoc.xml · nonDerivative · entry 5 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,240 Read SEC document |
| November 24, 2017 Filed Nov 24, 2017 22:16 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 500 | $0.50 | $247.50 |
DisclosureSEC source: 0001437749-17-019783 · rdgdoc.xml · nonDerivative · entry 4 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,725 Read SEC document |
| November 22, 2017 Filed Nov 24, 2017 22:16 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 1,825 | $0.49 | $894.25 |
DisclosureSEC source: 0001437749-17-019783 · rdgdoc.xml · nonDerivative · entry 3 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,225 Read SEC document |
| November 21, 2017 Filed Nov 24, 2017 22:16 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 3,400 | $0.49 | $1,649.00 |
DisclosureSEC source: 0001437749-17-019783 · rdgdoc.xml · nonDerivative · entry 2 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,400 Read SEC document |
| November 21, 2017 Filed Nov 24, 2017 22:16 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 2,000 | $0.47 | $942.00 |
DisclosureSEC source: 0001437749-17-019783 · rdgdoc.xml · nonDerivative · entry 1 Austin Mark John · CIK 0001713059 · Controller/Prin Fin&Acct Offic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.